Telomerase-Specific Replication-Selective Virotherapy for Human Cancer

Kawashima, Takeshi; Kagawa, Shunsuke; Kobayashi, Naoya; Shirakiya, Yoshiko; Umeoka, Tatsuo; Teraishi, Fuminori; Taki, Masaki; Kyo, Satoru; Tanaka, Noriaki; Fujiwara, Toshiyoshi

doi:10.1158/1078-0432.ccr-1075-3

Cited by 263Virus-based gene therapy researchTelomeres, Telomerase, and SenescenceCancer Research and Treatments

Telomerase-Specific Replication-Selective Virotherapy for Human Cancer

Kawashima, Takeshi, Kagawa, Shunsuke, Kobayashi, Naoya, Shirakiya, Yoshiko, Umeoka, Tatsuo, Teraishi, Fuminori, Taki, Masaki, Kyo, Satoru +2 more·2004·Clinical Cancer Research

DOI 10.1158/1078-0432.ccr-1075-3

Open this paper in CoChat — free account

Abstract

Purpose: Replication-selective tumor-specific viruses present a novel approach for treating neoplastic disease. These vectors are designed to induce virus-mediated lysis of tumor cells after selective viral propagation within the tumor. Telomerase activation is considered to be a critical step in carcinogenesis, and its activity is closely correlated with human telomerase reverse transcriptase (hTERT) expression. We investigated the antitumor effect of the hTERT-specific replication-competent adenovirus on human cancer cells. Experimental Design: We constructed an adenovirus 5 vector [tumor- or telomerase-specific replication-competent adenovirus (TRAD)], in which the hTERT promoter element drives expression of E1A and E1B genes linked with an internal ribosome entry site, and we examined the selective replication and antitumor effect in human cancer cells in vitro and in vivo. Results: TRAD induced selective E1A and E1B expression in human cancer cells, but not in normal cells such as human fibroblasts. TRAD replicated efficiently and induced marked cell killing in a panel of human cancer cell lines, whereas replication as well as cytotoxicity was highly attenuated in normal human fibroblasts lacking telomerase activity. In nu/nu mice carrying s.c. human lung tumor xenografts, intratumoral injection of TRAD resulted in a significant inhibition of tumor growth. No evidence of TRAD was identified in tissues outside of the tumors, despite the presence of TRAD in the circulation. Moreover, TRAD replication in the distant, noninjected tumors was demonstrated. Conclusions: Our results suggest that the hTERT promoter confers competence for selective replication of TRAD in human cancer cells, an outcome that has important implications for the treatment of human cancers.

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-1075-3

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Telomelysin (OBP-301) is a telomerase-dependent replication-competent adenovirus type 5 vector in which E1A and E1B genes are transcribed under the hTERT promoter.
“We developed a novel telomerase-dependent replicative adenovirus type 5 vector (Telomelysin, OBP-301) in which E1A and E1B genes, required for adenoviral replication, were transcribed under the hTERT promoter.(106)”
From Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers (2008) · cites this paper as [106]
Telomelysin efficiently kills a broad range of cancer cell types, including head and neck, lung, esophageal, pancreatic, hepatic, prostate, cervical cancers, melanoma, sarcoma, and mesothelioma.
“Indeed, Telomelysin could efficiently kill head and neck, lung, esophageal, pancreatic, hepatic, prostate, and cervical cancers, as well as melanoma, sarcoma, and mesothelioma cells.(106,110)”
From Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers (2008) · cites this paper as [106]

Specific Association of Human Telomerase Activity with Immortal Cells and Cancer
Kim, N. W., Piatyszek, M. A., Prowse, K. R., Harley, C. B., West, M. D., Ho, P. L. C., Coviello, G. M., Wright, W. E., Weinrich, S. L., & Shay, J. W. (1994) · Science · doi:10.1126/science.7605428 · Cited by 7,091 · cited 2× · see citing works
“Many studies have demonstrated that the majority of malignant tumors express telomerase activity (4), whereas most normal cells do not (5).”
Background
Structure and function of telomeres
Blackburn, E. H. (1991) · Nature · doi:10.1038/350569a0 · Cited by 3,596 · see citing works
Telomerase Catalytic Subunit Homologs from Fission Yeast and Human
Nakamura, T. M., Morin, G. B., Chapman, K. B., Weinrich, S. L., Andrews, W. H., Lingner, J., Harley, C. B., & Cech, T. R. (1997) · Science · doi:10.1126/science.277.5328.955 · Cited by 2,256 · see citing works
The RNA Component of Human Telomerase
Feng, J., Funk, W. D., Wang, S.-S., Weinrich, S. L., Avilion, A. A., Chiu, C.-P., Adams, R. R., Chang, E., Allsopp, R. C., Yu, J., et al. (1995) · Science · doi:10.1126/science.7544491 · Cited by 2,227 · see citing works
hEST2, the Putative Human Telomerase Catalytic Subunit Gene, Is Up-Regulated in Tumor Cells and during Immortalization
Meyerson, M., Counter, C. M., Eaton, E. N., Ellisen, L. W., Steiner, P., Caddle, S. D., Ziaugra, L., Beijersbergen, R. L., Davidoff, M. J., Liu, Q., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80538-3 · Cited by 1,784 · see citing works
An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells
Bischoff, J. R., Kirn, D. H., Williams, A., Heise, C. C., Horn, S. T., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A., et al. (1996) · Science · doi:10.1126/science.274.5286.373 · Cited by 1,753 · see citing works
A Mammalian Telomerase-Associated Protein
Harrington, L. A., McPhail, T., Mar, V. L., Zhou, W., Oulton, R., Program, A. E., Bass, M. B., Arruda, I., & Robinson, M. O. (1997) · Science · doi:10.1126/science.275.5302.973 · Cited by 666 · see citing works
Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas
Nakayama, J., Tahara, H., 栄治, 田., Saito, M., Ito, K., Nakamura, H., Nakanishi, T., Nakanishi, E., Ide, T., & Ishikawa, F. (1998) · Nature Genetics · doi:10.1038/ng0198-65 · Cited by 602 · see citing works
Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells.
Rodríguez, R., Schuur, E. R., Lim, H. Y., Henderson, G. A., Simons, J. W., & Henderson, D. (1997) · PubMed · Cited by 584 · see citing works
Replication-selective virotherapy for cancer: Biological principles, risk management and future directions
Kirn, D. H., Martuza, R. L., & Zwiebel, J. A. (2001) · Nature Medicine · doi:10.1038/89901 · Cited by 505 · see citing works
Adenovirus-Mediated p53 Gene Transfer in Advanced Non-Small-Cell Lung Cancer
Swisher, S. G., Roth, J. A., Nemunaitis, J. J., Lawrence, D. D., Kemp, B. L., Carrasco, C. H., Connors, D. G., El‐Naggar, A. K., Fossella, F. V., Glisson, B. S., et al. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.9.763 · Cited by 495 · see citing works
Cloning of human telomerase catalytic subunit(hTERT)gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells
高倉, 正. (2002) · Medical Entomology and Zoology · Cited by 475 · see citing works
Telomerase activity in human cancer
Shay, J. W., & Wright, W. E. (1996) · Current Opinion in Oncology · doi:10.1097/00001622-199601000-00012 · Cited by 404 · see citing works
Replication of ONYX-015, a Potential Anticancer Adenovirus, Is Independent of p53 Status in Tumor Cells
Rothmann, T., Hengstermann, A., Whitaker, N. J., Scheffner, M., & Hausen, H. Z. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.9470-9478.1998 · Cited by 349 · see citing works
Reconstitution of human telomerase activity in vitro
Beattie, T. L., Zhou, W., Robinson, M. O., & Harrington, L. A. (1998) · Current Biology · doi:10.1016/s0960-9822(98)70067-3 · Cited by 348 · see citing works
Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen
Kurihara, T., Brough, D. E., Kovesdi, I., & Kufe, D. W. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9180 · Cited by 237 · see citing works
Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers.
Gu, J. H., Kagawa, S., Takakura, M., Kyo, S., Inoue, M., Roth, J. A., & Fang, B. (2000) · PubMed · Cited by 186 · see citing works
Self-citation
A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer.
Wirth, T. C., Zender, L., Schulte, B., Mundt, B., Plentz, R. R., Rudolph, K. L., Manns, M. P., Kubicka, S., & Kühnel, F. (2003) · PubMed · Cited by 171 · see citing works
A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis.
Matsubara, S., Wada, Y., Gardner, T. A., Egawa, M., Park, M. S., Hsieh, C., Zhau, H. E., Kao, C. H., Kamidono, S., Gillenwater, J. Y., et al. (2001) · PubMed · Cited by 149 · see citing works
A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.
Li, Y., Yu, D., Chen, Y., Amin, P. R., Zhang, H., Nguyen, N., & Henderson, D. (2001) · PubMed · Cited by 147 · see citing works
Treatment of malignant glioma cells with the transfer of constitutively active caspase-6 using the human telomerase catalytic subunit (human telomerase reverse transcriptase) gene promoter.
Komata, T., Kondo, Y., Kanzawa, T., Hirohata, S., Koga, S., Sumiyoshi, H., Srinivasula, S. M., Barna, B. P., Germano, I. M., Takakura, M., et al. (2001) · PubMed · Cited by 130 · see citing works
Self-citation
Oncolytic activity of the E1B-55 kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts.
Geoerger, B., Grill, J., Opolon, P., Morizet, J., Aubert, G., Terrier‐Lacombe, M., Paillerets, B. B., Barrois, M., Feunteun, J., Kirn, D. H., et al. (2002) · PubMed · Cited by 117 · see citing works
A midkine promoter-based conditionally replicative adenovirus for treatment of pediatric solid tumors and bone marrow tumor purging.
Adachi, Y., Reynolds, P. N., Yamamoto, M., Wang, M., Takayama, K., Matsubara, S., Muramatsu, T., & Curiel, D. T. (2001) · PubMed · Cited by 97 · see citing works
Use of Transcriptional Regulatory Sequences of Telomerase (hTER and hTERT) for Selective Killing of Cancer Cells
Abdul‐Ghani, R., Ohana, P., Matouk, I., Ayesh, S. K., Ayesh, B. M., Laster, M., Bibi, O., Giladi, H., Molnar-Kimber, K. L., Sughayer, M. A., et al. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0196 · Cited by 89 · see citing works
An E2F-responsive replication-selective adenovirus targeted to the defective cell cycle in cancer cells: potent antitumoral efficacy but no toxicity to normal cell.
Tsukuda, K., Wiewrodt, R. G., Molnar-Kimber, K. L., Jovanovic, V. P., & Amin, K. M. (2002) · PubMed · Cited by 89 · see citing works
The use of the L-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines.
Peng, X., Won, J.-H., Rutherford, T., Fujii, T., Zelterman, D. A., Pizzorno, G., Sapi, E., Leavitt, J. C., Kacinski, B. M., Crystal, R. G., et al. (2001) · PubMed · Cited by 65 · see citing works
Caspase-8 Gene Therapy Using the Human Telomerase Reverse Transcriptase Promoter for Malignant Glioma Cells
Komata, T., Kondo, Y., Kanzawa, T., Ito, H., Hirohata, S., Koga, S., Sumiyoshi, H., Takakura, M., Inoue, M., Barna, B. P., et al. (2002) · Human Gene Therapy · doi:10.1089/104303402753812421 · Cited by 62 · see citing works
Self-citation
A novel treatment of human malignant gliomas in vitro and in vivo: FADD gene transfer under the control of the human telomerase reverse transcriptase gene promoter
Komata, T., Koga, S., Hirohata, S., Takakura, M., Germano, I. M., Inoue, M., Kyo, S., Kondo, S., & Kondo, Y. (2001) · International Journal of Oncology · doi:10.3892/ijo.19.5.1015 · Cited by 35 · see citing works
Self-citation
The NH(2)-terminal and conserved region 2 domains of adenovirus E1A mediate two distinct mechanisms of tumor suppression.
Deng, J., Kloosterbooer, F., Xia, W., & Hung, M. (2002) · PubMed · Cited by 26 · see citing works
A telomerase dependent conditionally replicating adenovirus for treatment of hepatocellular carcinoma
Wirth, T. C., Zender, L., Schulte, B., Mundt, B., Plentz, R. R., Rudolph, K. L., Manns, M. P., Kuehnel, F., & Kubicka, S. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)80118-6 · Cited by 5 · see citing works

Flagged first, then by citations

Sorted by citations

Treatment of Liver CancerPreprint
Liu, C., Chen, K., & Chen, P. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a021535 · Cited by 401 · see citing works
Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers
Kyo, S., Takakura, M., Fujiwara, T., & Inoue, M. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00878.x · Cited by 347 · see citing works
Self-citation
Novel anticancer therapeutics targeting telomerase
Ruden, M., & Puri, N. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.06.007 · Cited by 309 · see citing works
A Phase I Study of Telomerase-specific Replication Competent Oncolytic Adenovirus (Telomelysin) for Various Solid Tumors
Nemunaitis, J. J., Tong, A. W., Nemunaitis, M., Senzer, N. N., Phadke, A. P., Bedell, C., Adams, N., Zhang, Y.-A., Maples, P. B., Chen, S., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.262 · Cited by 266 · see citing works
Self-citation
Targeting telomerase for cancer therapy
Guterres, A. N., & Villanueva, J. (2020) · Oncogene · doi:10.1038/s41388-020-01405-w · Cited by 256 · see citing works
In vivo imaging of lymph node metastasis with telomerase-specific replication-selective adenovirus
Kishimoto, H., Kojima, T., Watanabe, Y., Kagawa, S., Fujiwara, T., Uno, F., Teraishi, F., Kyo, S., Mizuguchi, H., Hashimoto, Y., et al. (2006) · Nature Medicine · doi:10.1038/nm1404 · Cited by 179 · see citing works
Self-citation
Autophagic Cell Death of Malignant Glioma Cells Induced by a Conditionally Replicating Adenovirus
Ito, H., Aoki, H., Kühnel, F., Kondo, Y., Kubicka, S., Wirth, T. C., Iwado, E., Iwamaru, A., Fujiwara, K., Hess, K. R., et al. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj161 · Cited by 176 · see citing works
Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis
Dorer, D. E., & Nettelbeck, D. M. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.03.013 · Cited by 150 · see citing works
Is telomerase a viable target in cancer?
Buseman, C. M., Wright, W. E., & Shay, J. W. (2011) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2011.07.006 · Cited by 145 · see citing works
hTERT: a novel endogenous inhibitor of the mitochondrial cell death pathway
Massard, C., Zermati, Y., Pauleau, A.-L., Larochette, N., Métivier, D., Sabatier, L., Kroemer, G., & Soria, J.-C. (2006) · Oncogene · doi:10.1038/sj.onc.1209487 · Cited by 144 · see citing works
In vivo internal tumor illumination by telomerase-dependent adenoviral GFP for precise surgical navigation
Kishimoto, H., Zhao, M. D., Hayashi, K., Urata, Y., Tanaka, N., Fujiwara, T., Penman, S., & Hoffman, R. M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906388106 · Cited by 141 · see citing works
Self-citation
Telomeres and telomerase in prostate cancer development and therapy
Graham, M. K., & Meeker, A. K. (2017) · Nature Reviews Urology · doi:10.1038/nrurol.2017.104 · Cited by 122 · see citing works
Adenovirus receptors and their implications in gene delivery
Sharma, A., Li, X., Bangari, D. S., & Mittal, S. K. (2009) · Virus Research · doi:10.1016/j.virusres.2009.02.010 · Cited by 122 · see citing works
Adenovirus Biology, Recombinant Adenovirus, and Adenovirus Usage in Gene Therapy
WATANABE, M., Nishikawaji, Y., Kawakami, H., & Kosai, K.-I. (2021) · Viruses · doi:10.3390/v13122502 · Cited by 118 · see citing works
A simple biological imaging system for detecting viable human circulating tumor cells
Kojima, T., Hashimoto, Y., Watanabe, Y., Kagawa, S., Uno, F., Kuroda, S., Tazawa, H., Kyo, S., Mizuguchi, H., Urata, Y., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38609 · Cited by 116 · see citing works
Self-citation
Clinical development directions in oncolytic viral therapy
Eager, R. M., & Nemunaitis, J. J. (2011) · Cancer Gene Therapy · doi:10.1038/cgt.2011.7 · Cited by 110 · see citing works
Telomere and Telomerase Therapeutics in Cancer
Xu, Y., & Goldkorn, A. (2016) · Genes · doi:10.3390/genes7060022 · Cited by 109 · see citing works
Improving antitumor efficacy via combinatorial regimens of oncolytic virotherapy
Zhang, B., & Cheng, P. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01275-6 · Cited by 101 · see citing works
Concepts in Oncolytic Adenovirus Therapy
Mantwill, K., Klein, F. G., Wang, D., Hindupur, S. V., Ehrenfeld, M., Holm, P. S., & Nawroth, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910522 · Cited by 97 · see citing works
Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells
Watanabe, T., Hioki, M., Fujiwara, T., Nishizaki, M., Kagawa, S., Taki, M., Kishimoto, H., Endo, Y., Urata, Y., Tanaka, N., et al. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2005.10.026 · Cited by 88 · see citing works
Self-citation
Virus-mediated oncolysis induces danger signal and stimulates cytotoxic T-lymphocyte activity via proteasome activator upregulation
Endo, Y., Sakai, R., Ouchi, M., Onimatsu, H., Hioki, M., Kagawa, S., Uno, F., Watanabe, Y., Urata, Y., Tanaka, N., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210884 · Cited by 87 · see citing works
Self-citation
Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 (‘Telomelysin-RGD’)
Taki, M., Kagawa, S., Nishizaki, M., Mizuguchi, H., Hayakawa, T., Kyo, S., Nagai, K., Urata, Y., Tanaka, N., & Fujiwara, T. (2005) · Oncogene · doi:10.1038/sj.onc.1208460 · Cited by 86 · see citing works
Self-citation
ALT Positivity in Human Cancers: Prevalence and Clinical Insights
MacKenzie, D., Watters, A. K., To, J. T., Young, M. W., Muratori, J., Wilkoff, M. H., Abraham, R. G., Plummer, M. M., & Zhang, D. (2021) · Cancers · doi:10.3390/cancers13102384 · Cited by 85 · see citing works
Targeting telomerase-expressing cancer cells
Ouellette, M. M., Wright, W. E., & Shay, J. W. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01279.x · Cited by 82 · see citing works
A Multiscale Mathematical Model for Oncolytic Virotherapy
Paiva, L. R., Binny, C., Ferreira, S. C., & Martins, M. L. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2173 · Cited by 82 · see citing works
Oncolytic virus therapy in Japan: progress in clinical trials and future perspectives
Taguchi, S., Fukuhara, H., & Todo, T. (2018) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyy170 · Cited by 78 · see citing works
Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody
Kanaya, N., Kuroda, S., Kakiuchi, Y., Kumon, K., Tsumura, T., Hashimoto, M., Morihiro, T., Kubota, T., Aoyama, K., Kikuchi, S., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.01.003 · Cited by 78 · see citing works
Self-citation
Telomerase-Dependent Oncolytic Adenovirus Sensitizes Human Cancer Cells to Ionizing Radiation via Inhibition of DNA Repair Machinery
Kuroda, S., Fujiwara, T., Shirakawa, Y., Yamasaki, Y., Yano, S., Uno, F., Tazawa, H., Hashimoto, Y., Watanabe, Y., Noma, K., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2333 · Cited by 78 · see citing works
Self-citation
Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives
Chen, G., Zhang, S. J., He, X., Liu, S., Ma, C., & Zou, X. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s50483 · Cited by 76 · see citing works
Phase I dose-escalation study of endoscopic intratumoral injection of OBP-301 (Telomelysin) with radiotherapy in oesophageal cancer patients unfit for standard treatments
Shirakawa, Y., Tazawa, H., Tanabe, S., Kanaya, N., Noma, K., Koujima, T., Kashima, H., Kato, T., Kuroda, S., Kikuchi, S., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.04.043 · Cited by 76 · see citing works
Self-citation
Establishment of biological and pharmacokinetic assays of telomerase‐specific replication‐selective adenovirus
Hashimoto, Y., Watanabe, Y., Shirakiya, Y., Uno, F., Kagawa, S., Kawamura, H., Nagai, K., Tanaka, N., Kumon, H., Urata, Y., et al. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2007.00665.x · Cited by 76 · see citing works
Self-citation
From Benchtop to Bedside: A Review of Oncolytic Virotherapy
Choi, A. H., O’Leary, M., Fong, Y., & Chen, N. G. (2016) · Biomedicines · doi:10.3390/biomedicines4030018 · Cited by 74 · see citing works
Enhanced antitumor efficacy of telomerase‐selective oncolytic adenoviral agent OBP‐401 with docetaxel: Preclinical evaluation of chemovirotherapy
Fujiwara, T., Kagawa, S., Kishimoto, H., Endo, Y., Hioki, M., Ikeda, Y., Sakai, R., Urata, Y., Tanaka, N., & Fujiwara, T. (2006) · International Journal of Cancer · doi:10.1002/ijc.21846 · Cited by 73 · see citing works
Self-citation
A Genetically Engineered Oncolytic Adenovirus Decoys and Lethally Traps Quiescent Cancer Stem–like Cells in S/G2/M Phases
Yano, S., Tazawa, H., Hashimoto, Y., Shirakawa, Y., Kuroda, S., Nishizaki, M., Kishimoto, H., Uno, F., Nagasaka, T., Urata, Y., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0742 · Cited by 73 · see citing works
Self-citation
Visualization of Intrathoracically Disseminated Solid Tumors in Mice with Optical Imaging by Telomerase-Specific Amplification of a Transferred Green Fluorescent Protein Gene
Umeoka, T., Kawashima, T., Kagawa, S., Teraishi, F., Taki, M., Nishizaki, M., Kyo, S., Nagai, K., Urata, Y., Tanaka, N., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1335 · Cited by 72 · see citing works
Self-citation
Telomerase-Dependent Virotherapy Overcomes Resistance of Hepatocellular Carcinomas against Chemotherapy and Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand by Elimination of Mcl-1
Wirth, T., Kühnel, F., Fleischmann-Mundt, B., Woller, N., Djojosubroto, M., Rudolph, K. L., Manns, M., Zender, L., & Kubicka, S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3664 · Cited by 65 · see citing works
Dual Programmed Cell Death Pathways Induced by p53 Transactivation Overcome Resistance to Oncolytic Adenovirus in Human Osteosarcoma Cells
Hasei, J., Sasaki, T., Tazawa, H., Osaki, S., Yamakawa, Y., Kunisada, T., Yoshida, A., Hashimoto, Y., Onishi, T., Uno, F., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0869 · Cited by 65 · see citing works
Self-citation
Selective metastatic tumor labeling with green fluorescent protein and killing by systemic administration of telomerase-dependent adenoviruses
Kishimoto, H., Urata, Y., Tanaka, N., Fujiwara, T., & Hoffman, R. M. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0556 · Cited by 64 · see citing works
Self-citation
Advances in adenovirus-mediated p53 cancer gene therapy
Tazawa, H., Kagawa, S., & Fujiwara, T. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.845662 · Cited by 64 · see citing works
Self-citation
Anti-Tumor Activity of a miR-199-dependent Oncolytic Adenovirus
Callegari, E., Elamin, B. K., D’Abundo, L., Falzoni, S., Donvito, G., Moshiri, F., Milazzo, M., Altavilla, G., Giacomelli, L., Fornari, F., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073964 · Cited by 64 · see citing works
Immune Gene–Viral Therapy with Triplex Efficacy Mediated by Oncolytic Adenovirus Carrying an Interferon-γ Gene Yields Efficient Antitumor Activity in Immunodeficient and Immunocompetent Mice
Su, C., Peng, L., Sham, J. S. T., Wang, X., Zhang, Q., Chua, D. T.-T., Liu, C., Cui, Z., Xue, H., Wu, H., et al. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.12.011 · Cited by 64 · see citing works
A review on the advances and challenges of immunotherapy for head and neck cancer
Cheng, G., Dong, H., Yang, C., Yang, L., Wu, Y., Zhu, L., Tong, X., & Wang, S. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02024-5 · Cited by 63 · see citing works
A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression
Yamasaki, Y., Tazawa, H., Hashimoto, Y., Kojima, T., Kuroda, S., Yano, S., Yoshida, R., Uno, F., Mizuguchi, H., Ohtsuru, A., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.12.020 · Cited by 62 · see citing works
Self-citation
Telomeres and telomerase as targets for cancer therapy
Zimmermann, S., & Martens, U. M. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-6481-8 · Cited by 62 · see citing works
Adenoviral Vector-Based Strategies for Cancer Therapy
Sharma, A., Tandon, M., Bangari, D. S., & Mittal, S. K. (2009) · Current Drug Therapy · doi:10.2174/157488509788185123 · Cited by 60 · see citing works
Oncolytic Adenovirus in Cancer Immunotherapy
Peter, M., & Kühnel, F. (2020) · Cancers · doi:10.3390/cancers12113354 · Cited by 57 · see citing works
An oncolytic adenovirus expressing granulocyte macrophage colony-stimulating factor shows improved specificity and efficacy for treating human solid tumors
Lei, N., Shen, F., Chang, J. H., Wang, L., Li, H., Yang, C., Li, J., & Yu, D. (2008) · Cancer Gene Therapy · doi:10.1038/cgt.2008.46 · Cited by 56 · see citing works
Genetically engineered oncolytic adenovirus induces autophagic cell death through an E2F1‐microRNA‐7‐epidermal growth factor receptor axis
Tazawa, H., Yano, S., Yoshida, R., Yamasaki, Y., Sasaki, T., Hashimoto, Y., Kuroda, S., Ouchi, M., Onishi, T., Uno, F., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27589 · Cited by 56 · see citing works
Self-citation
Impact of Autophagy in Oncolytic Adenoviral Therapy for Cancer
Tazawa, H., Kuroda, S., Hasei, J., Kagawa, S., & Fujiwara, T. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071479 · Cited by 56 · see citing works
Self-citation
Preclinical Evaluation of Telomerase-Specific Oncolytic Virotherapy for Human Bone and Soft Tissue Sarcomas
Sasaki, T., Tazawa, H., Hasei, J., Kunisada, T., Yoshida, A., Hashimoto, Y., Yano, S., Yoshida, R., Uno, F., Kagawa, S., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2066 · Cited by 55 · see citing works
Self-citation
Telomerase as an emerging target to fight cancer — Opportunities and challenges for nanomedicine
Philippi, C., Loretz, B., Schaefer, U. F., & Lehr, C. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.03.025 · Cited by 54 · see citing works
Telomerase Inhibition in Cancer Therapeutics: Molecular-Based Approaches
Publisher, B. S. P. B. S. (2006) · Current Medicinal Chemistry · doi:10.2174/092986706778521887 · Cited by 52 · see citing works
Intraperitoneal administration of telomerase-specific oncolytic adenovirus sensitizes ovarian cancer cells to cisplatin and affects survival in a xenograft model with peritoneal dissemination
Takakura, M., Nakamura, M., Kyo, S., HASHIMOTO, M. W., Mori, N., Ikoma, T., Mizumoto, Y., Fujiwara, T., Urata, Y., & Inoue, M. (2009) · Cancer Gene Therapy · doi:10.1038/cgt.2009.44 · Cited by 52 · see citing works
Self-citation
Preclinical evaluation of synergistic effect of telomerase-specific oncolytic virotherapy and gemcitabine for human lung cancer
Liu, D., Kojima, T., Ouchi, M., Kuroda, S., Watanabe, Y., Hashimoto, Y., Onimatsu, H., Urata, Y., & Fujiwara, T. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0901 · Cited by 51 · see citing works
Self-citation
Oncolytic virus-mediated p53 overexpression promotes immunogenic cell death and efficacy of PD-1 blockade in pancreatic cancer
Araki, H., Tazawa, H., Kanaya, N., Kajiwara, Y., Yamada, M., Hashimoto, M., Kikuchi, S., Kuroda, S., Yoshida, R., Umeda, Y., et al. (2022) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2022.09.003 · Cited by 50 · see citing works
Self-citation
Recent Clinical Experience with Oncolytic Viruses
Donnelly, O., Errington‐Mais, F., Prestwich, R. J. D., Harrington, K. J., Pandha, H., Vile, R. G., & Melcher, A. A. (2012) · Current Pharmaceutical Biotechnology · doi:10.2174/138920112800958904 · Cited by 48 · see citing works
Targeting homologous recombination-mediated DNA repair in cancer
Carvalho, J. F. S., & Kanaar, R. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.882900 · Cited by 46 · see citing works
Ablation of MCL1 expression by virally induced microRNA-29 reverses chemoresistance in human osteosarcomas
Osaki, S., Tazawa, H., Hasei, J., Yamakawa, Y., Omori, T., Sugiu, K., Komatsubara, T., Fujiwara, T., Sasaki, T., Kunisada, T., et al. (2016) · Scientific Reports · doi:10.1038/srep28953 · Cited by 45 · see citing works
Self-citation
Drug Insight: cancer cell immortality—telomerase as a target for novel cancer gene therapies
Keith, W. N., Bilsland, A. E., Hardie, M., & Evans, T. J. (2004) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0044 · Cited by 44 · see citing works
Oncolytic adenovirus with MUC16-BiTE shows enhanced antitumor immune response by reversing the tumor microenvironment in PDX model of ovarian cancer
Wang, Q., Ma, X., Wu, H., Zhao, C., Chen, J., Li, R., Yan, S., Li, Y., Zhang, Q., Song, K., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2096362 · Cited by 43 · see citing works
Oncolytic Virus-Mediated Targeting of the ERK Signaling Pathway Inhibits Invasive Propensity in Human Pancreatic Cancer
Koujima, T., Tazawa, H., Ieda, T., Araki, H., Fushimi, T., Shoji, R., Kuroda, S., Kikuchi, S., Yoshida, R., Umeda, Y., et al. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.03.016 · Cited by 43 · see citing works
Self-citation
Local oncolytic adenovirotherapy produces an abscopal effect via tumor-derived extracellular vesicles
Kakiuchi, Y., Kuroda, S., Kanaya, N., Kumon, K., Tsumura, T., Hashimoto, M., Yagi, C., Sugimoto, R., Hamada, Y., Kikuchi, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.05.015 · Cited by 42 · see citing works
Self-citation
Energetics of Quadruplex-Drug Recognition in Anticancer Therapy
Pagano, B., & Giancola, C. (2007) · Current Cancer Drug Targets · doi:10.2174/156800907781662257 · Cited by 42 · see citing works
Apoptosis pathways and oncolytic adenoviral vectors: promising targets and tools to overcome therapy resistance of malignant melanoma
Eberle, J., Fecker, L. F., Hossini, A. M., Kurbanov, B. M., & Fechner, H. (2007) · Experimental Dermatology · doi:10.1111/j.1600-0625.2007.00655.x · Cited by 41 · see citing works
Safety and dose escalation of the targeted oncolytic adenovirus OBP-301 for refractory advanced liver cancer: Phase I clinical trial
Heo, J., Liang, J., Kim, C. W., Woo, H. Y., Shih, I., Su, T., Lin, Z., Yoo, S. Y., Chang, S., Urata, Y., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.04.006 · Cited by 40 · see citing works
Adenovirus as a Vector and Oncolytic Virus
Matsunaga, W., & Gotoh, A. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45060307 · Cited by 39 · see citing works
Bone Repair by Transplantation of hTERT-Immortalized Human Mesenchymal Stem Cells in Mice
Nakahara, H., Misawa, H., Hayashi, T., Kondo, E., Yuasa, T., Kubota, Y., Seita, M., Kawamoto, H., Hassan, W. A. R. A., Hassan, R. A. R. A., et al. (2009) · Transplantation · doi:10.1097/tp.0b013e3181ae5ba2 · Cited by 39 · see citing works
Self-citation
Oncolytic adenovirus that overproduces ADP and replicates selectively in tumors due to hTERT promoter-regulated E4 gene expression
Kuppuswamy, M. N., Spencer, J. F., Doronin, K., Tollefson, A. E., Wold, W. S. M., & Tóth, K. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302581 · Cited by 39 · see citing works
Enhanced Safety Profiles of the Telomerase-Specific Replication-Competent Adenovirus by Incorporation of Normal Cell-Specific microRNA-Targeted Sequences
Sugio, K., Sakurai, F., Katayama, K., Tashiro, K., Matsui, H., Kawabata, K., Kawase, A., Iwaki, M., Hayakawa, T., Fujiwara, T., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2008 · Cited by 38 · see citing works
Self-citation
Liposome-encapsulated plasmid DNA of telomerase-specific oncolytic adenovirus with stealth effect on the immune system
Aoyama, K., Kuroda, S., Morihiro, T., Kanaya, N., Kubota, T., Kakiuchi, Y., Kikuchi, S., Nishizaki, M., Kagawa, S., Tazawa, H., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-14717-x · Cited by 38 · see citing works
Self-citation
Boosting Replication and Penetration of Oncolytic Adenovirus by Paclitaxel Eradicate Peritoneal Metastasis of Gastric Cancer
Ishikawa, W., Kikuchi, S., Ogawa, T., Tabuchi, M., Tazawa, H., Kuroda, S., Noma, K., Nishizaki, M., Kagawa, S., Urata, Y., et al. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.06.021 · Cited by 37 · see citing works
Self-citation
Direct and distant antitumor effects of a telomerase-selective oncolytic adenoviral agent, OBP-301, in a mouse prostate cancer model
Huang, P., Watanabe, M., Kaku, H., Kashiwakura, Y., Chen, J., Saika, T., Nasu, Y., Fujiwara, T., Urata, Y., & Kumon, H. (2008) · Cancer Gene Therapy · doi:10.1038/cgt.2008.3 · Cited by 37 · see citing works
Self-citation
Telomerase as a new target for the treatment of hormone-refractory prostate cancer
Biroccio, A., & Leonetti, C. (2004) · Endocrine Related Cancer · doi:10.1677/erc.1.00764 · Cited by 37 · see citing works
Telomerase as a therapeutic target in cancer
Gellert, G. C., Jackson, S. R., Dikmen, Z. G., Wright, W. E., & Shay, J. W. (2005) · Drug Discovery Today Disease Mechanisms · doi:10.1016/j.ddmec.2005.05.009 · Cited by 37 · see citing works
Ataxia-telangiectasia mutated and the Mre11-Rad50-NBS1 complex: promising targets for radiosensitization.
Kuroda, S., Urata, Y., & Fujiwara, T. (2012) · PubMed · doi:10.18926/amo/48258 · Cited by 36 · see citing works
Self-citation
Oncolytic virus-mediated reducing of myeloid-derived suppressor cells enhances the efficacy of PD-L1 blockade in gemcitabine-resistant pancreatic cancer
Kajiwara, Y., Tazawa, H., Yamada, M., Kanaya, N., Fushimi, T., Kikuchi, S., Kuroda, S., Ohara, T., Noma, K., Yoshida, R., et al. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03334-x · Cited by 36 · see citing works
Self-citation
FUCCI Real-Time Cell-Cycle Imaging as a Guide for Designing Improved Cancer Therapy: A Review of Innovative Strategies to Target Quiescent Chemo-Resistant Cancer Cells
Yano, S., Tazawa, H., Kagawa, S., Fujiwara, T., & Hoffman, R. M. (2020) · Cancers · doi:10.3390/cancers12092655 · Cited by 35 · see citing works
Self-citation
Systemic Management for Advanced Hepatocellular Carcinoma: A Review of the Molecular Pathways of Carcinogenesis, Current and Emerging Therapies, and Novel Treatment Strategies
Saffo, S., & Taddei, T. H. (2019) · Digestive Diseases and Sciences · doi:10.1007/s10620-019-05582-x · Cited by 33 · see citing works
The antitumor effects of oncolytic adenovirus H101 against lung cancer
Lei, J., Li, Q., Yang, J.-L., LIU, F., Wang, L., Xu, W., & Zhao, W. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3045 · Cited by 33 · see citing works
A novel translational approach for human malignant pleural mesothelioma: heparanase-assisted dual virotherapy
Watanabe, Y., Kojima, T., Kagawa, S., Uno, F., Hashimoto, Y., Kyo, S., Mizuguchi, H., Tanaka, N., Kawamura, H., Ichimaru, D., et al. (2009) · Oncogene · doi:10.1038/onc.2009.415 · Cited by 33 · see citing works
Self-citation
In Vivo Biological Purging for Lymph Node Metastasis of Human Colorectal Cancer by Telomerase-Specific Oncolytic Virotherapy
Kojima, T., Watanabe, Y., Hashimoto, Y., Kuroda, S., Yamasaki, Y., Yano, S., Ouchi, M., Tazawa, H., Uno, F., Kagawa, S., et al. (2010) · Annals of Surgery · doi:10.1097/sla.0b013e3181deb69d · Cited by 33 · see citing works
Self-citation
Combining old and new concepts in targeting telomerase for cancer therapy: transient, immediate, complete and combinatory attack (TICCA)
Ali, J. H., & Walter, M. (2023) · Cancer Cell International · doi:10.1186/s12935-023-03041-2 · Cited by 32 · see citing works
Modulation of Telomerase Promoter Tumor Selectivity in the Context of Oncolytic Adenoviruses
Bilsland, A. E., Merron, A., Vassaux, G., & Keith, W. N. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3000 · Cited by 32 · see citing works
Potent antitumoral efficacy of a novel replicative adenovirus CNHK300 targeting telomerase-positive cancer cells
Su, C., Sham, J. S. T., Xue, H., Wang, X.-H., Chua, D., Cui, Z.-F., Peng, L., Li, L.-F., Jiang, L., Wu, M., et al. (2004) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-004-0577-4 · Cited by 32 · see citing works
Oncolytic adenoviruses as a therapeutic approach for osteosarcoma: A new hope
García-Moure, M., Martínez-Vélez, N., Patiño‐García, A., & Alonso, M. M. (2016) · Journal of bone oncology · doi:10.1016/j.jbo.2016.12.001 · Cited by 30 · see citing works
Telomerase-specific oncolytic immunotherapy for promoting efficacy of PD-1 blockade in osteosarcoma
Mochizuki, Y., Tazawa, H., Demiya, K., Kure, M., Kondo, H., Komatsubara, T., Sugiu, K., Hasei, J., Yoshida, A., Kunisada, T., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02774-7 · Cited by 30 · see citing works
Self-citation
Multiple Actions of Telomerase Reverse Transcriptase in Cell Death Regulation
Palamarchuk, A. I., Kovalenko, E. I., & Streltsova, M. A. (2023) · Biomedicines · doi:10.3390/biomedicines11041091 · Cited by 30 · see citing works
Telomerase-Specific Virotheranostics for Human Head and Neck Cancer
Kurihara, Y., Watanabe, Y., Onimatsu, H., Kojima, T., Shirota, T., Hatori, M., Liu, D., Kyo, S., Mizuguchi, H., Urata, Y., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2690 · Cited by 30 · see citing works
Self-citation
Gene-Viral Cancer Therapy Using Dual-Regulated Oncolytic Adenovirus with Antiangiogenesis Gene for Increased Efficacy
Su, C., Na, M., Chen, J., Wang, X., Liu, Y., Wang, W., Zhang, Q., Li, L., Long, J., Liu, X., et al. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0073 · Cited by 29 · see citing works
Real-Time Determination of the Cell-Cycle Position of Individual Cells within Live Tumors Using FUCCI Cell-Cycle Imaging
Yano, S., & Hoffman, R. M. (2018) · Cells · doi:10.3390/cells7100168 · Cited by 29 · see citing works
Role of Gene Therapy in Pancreatic Cancer—A Review
Sato‐Dahlman, M., Wirth, K. M., & Yamamoto, M. (2018) · Cancers · doi:10.3390/cancers10040103 · Cited by 28 · see citing works
High-dose VitC plus oncolytic adenoviruses enhance immunogenic tumor cell death and reprogram tumor immune microenvironment
Ma, J., Zhang, C., Shi, G., Yue, D., Shu, Y., Hu, S., Qi, Z., Chen, Y., Zhang, B., Zhang, Y., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.09.015 · Cited by 28 · see citing works
Oncolytic adenoviruses as antiglioma agents
Jiang, H., McCormick, F. P., Lang, F. F., Gomez‐Manzano, C., & Fueyo-Margareto, J. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.5.697 · Cited by 28 · see citing works
Trastuzumab-Based Photoimmunotherapy Integrated with Viral HER2 Transduction Inhibits Peritoneally Disseminated HER2-Negative Cancer
Ishida, M., Kagawa, S., Shimoyama, K., Takehara, K., Noma, K., Tanabe, S., Shirakawa, Y., Tazawa, H., Kobayashi, H., & Fujiwara, T. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0644 · Cited by 27 · see citing works
Self-citation
Efficient detection of human circulating tumor cells without significant production of false-positive cells by a novel conditionally replicating adenovirus
Sakurai, F., Narii, N., Tomita, K., Togo, S., Takahashi, K., Machitani, M., Tachibana, M., Ouchi, M., Katagiri, N., Urata, Y., et al. (2016) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2016.1 · Cited by 27 · see citing works
Self-citation
Effects of pre-existing anti-adenovirus antibodies on transgene expression levels and therapeutic efficacies of arming oncolytic adenovirus
Ono, R., Nishimae, F., Wakida, T., Sakurai, F., & Mizuguchi, H. (2022) · Scientific Reports · doi:10.1038/s41598-022-26030-3 · Cited by 26 · see citing works
A Renaissance for Oncolytic Adenoviruses?
Blanchette, P., & Teodoro, J. G. (2023) · Viruses · doi:10.3390/v15020358 · Cited by 26 · see citing works
Bone and Soft-Tissue Sarcoma: A New Target for Telomerase-Specific Oncolytic Virotherapy
Tazawa, H., Hasei, J., Yano, S., Kagawa, S., Ozaki, T., & Fujiwara, T. (2020) · Cancers · doi:10.3390/cancers12020478 · Cited by 26 · see citing works
Self-citation
Modulation of p53 expression in cancer-associated fibroblasts prevents peritoneal metastasis of gastric cancer
Ogawa, T., Kikuchi, S., Tabuchi, M., Mitsui, E., Une, Y., Tazawa, H., Kuroda, S., Noma, K., Ohara, T., Kagawa, S., et al. (2022) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2022.04.009 · Cited by 25 · see citing works
Self-citation
A novel oHSV-1 targeting telomerase reverse transcriptase-positive cancer cells via tumor-specific promoters regulating the expression of ICP4
Zhang, W., Ge, K., Zhao, Q., Zhuang, X., Deng, Z., Liu, L., Li, J., Zhang, Y., Dong, Y., Zhang, Y., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3884 · Cited by 25 · see citing works

Telomerase-Specific Oncolytic Virotherapy for Human Cancer with the hTERT Promoter
Fujiwara, T., Urata, Y., & Tanaka, N. (2007) · Current Cancer Drug Targets · doi:10.2174/156800907780058835 · Cited by 66 · see citing works
Self-citation
Replication of an adenoviral vector controlled by the human telomerase reverse transcriptase promoter causes tumor-selective tumor lysis.
Lanson, N. A., Friedlander, P. L., Schwarzenberger, P. O., Kolls, J. K., & Wang, G. (2003) · PubMed · Cited by 80 · see citing works
Targeted Oncolytic Adenovirus for Human Cancer Therapy: Gene-Based Therapies for Cancer
Fujiwara, T. (2010) · Springer eBooks · doi:10.1007/978-1-4419-6102-0_6 · Cited by 2 · see citing works
Self-citation
A novel telomerase-specific oncolytic virotherapy for human cancer: preclinical evaluation of safety, biodistribution, and efficacy
Fujiwara, T., Kagawa, S., Kawamura, H., Nagai, K., Nohara, R., Tanaka, N., & Urata, Y. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.13057
Self-citation
Development of a Conditional Replication Competent Adenovirus, Controlled by the Human Telomerase Promoter (hTERT)
Kim, E., Kim, J. H., Shin, H. Y., Lee, H., Sohn, J., Yang, J. M., Kim, J., & Yun, C. (2003) · Cancer Research and Treatment · doi:10.4143/crt.2003.35.3.191 · Cited by 3 · see citing works

Authors: Kawashima, T., Kagawa, S., Kobayashi, N., Shirakiya, Y., Umeoka, T., Teraishi, F., Taki, M., Kyo, S., Tanaka, N., & Fujiwara, T.
Affiliations: Okayama University (JP)
Kanazawa University (JP)
ORCID: Kagawa, Shunsuke
Kobayashi, Naoya
Teraishi, Fuminori
Kyo, Satoru
Fujiwara, Toshiyoshi
Venue: Clinical Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2004-01-01
Volume: 10
Issue: 1
Pages: 285-292
ISSN: 1078-0432 (ISSN-L)
1557-3265
DOI: 10.1158/1078-0432.ccr-1075-3
OpenAlex: W2128023051
Cited by: 262
References: 30
Citations by year: 2026: 9 · 2025: 15 · 2024: 10 · 2023: 19 · 2022: 9 · 2021: 16 · 2020: 15 · 2019: 3 · 2018: 10 · 2017: 7 · 2016: 13 · 2015: 7 · 2014: 5 · 2013: 12 · 2012: 15
FWCI: 6.43
Type: journal article
Language: en
Open access: closed
Locations: Clinical Cancer Research (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Health Sciences › Medicine › Physiology › Telomeres, Telomerase, and Senescence
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Cancer Research and Treatments
Keywords: telomerase, human telomerase reverse transcriptase, replication-competent adenovirus, virotherapy, hTERT promoter, internal ribosome entry site, anticancer activity, intratumoral injection, tumor growth inhibition
MeSH terms: Adenoviridae, Adenoviridae Infections, Animals, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Cytopathogenic Effect, Viral, Female, Fibroblasts, Genetic Vectors, Humans, Lung Neoplasms, Mice, Inbred BALB C, Mice, Nude, Promoter Regions, Genetic, Virus Replication, Gene Expression Regulation, Viral, Gene Expression Regulation, Neoplastic, Apoptosis, Adenovirus E1 Proteins, Telomerase, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice, In Vitro Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Telomerase-Specific Replication-Selective Virotherapy for Human Cancer

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks